.jpg?format=webp&width=780)
Topical intranasal anticholinergics are commonly prescribed for the relief of chronic rhinitis and associated symptoms. The present systematic review and meta‐analysis demonstrates that compared to placebo, anticholinergic treatment significantly reduced rhinorrhea severity and duration in allergic and non‐allergic rhinitis patients, albeit with significantly greater adverse event risk for epistaxis. Intranasal anticholinergics are a relatively safe, accessible, and effective option for patients suffering from rhinorrhea secondary to allergic or non‐allergic rhinitis and is most optimally used in a symptom‐specific role.
Like
Save
Share